J Gynecol Oncol.  2014 Apr;25(2):148-154. 10.3802/jgo.2014.25.2.148.

Building a successful fertility preservation program at a major cancer center

• Kim J
• Kim KH
• Mersereau

• KMID: 1708338
• DOI: http://doi.org/10.3802/jgo.2014.25.2.148

Abstract

Over 150,000 reproductive age individuals face fertility-threatening cancer treatments each year. Improved detection and treatment of cancer in reproductive-age patients have greatly increased the long-term survival and made it possible for these individuals to consider their long-term quality-of-life after cancer including having biologic offspring. Various methods of fertility preservation (FP) are now available for both males and females. In order to maximize FP options available to patients facing imminent gonadotoxic therapies, it is crucial that women have quick access to FP care and that providers expedite FP strategies. The overarching goal of a clinical FP program is to help patients and their physicians consider the impact of treatment on future fertility and facilitate FP efforts in what is often a limited time period before cancer treatment begins.

Keyword

Cancer center; Fertility preservation; Program

MeSH Terms

Female
Fertility Preservation*
Fertility*
Humans
Male

Reference

1. Garvelink MM, Ter Kuile MM, Bakker RM, Geense WJ, Jenninga E, Louwe LA, et al. Women's experiences with information provision and deciding about fertility preservation in the Netherlands: 'satisfaction in general, but unmet needs'. Health Expect. 2013; 05. 05. [Epub]. http://dx.doi.org/10.1111/hex.12068.

2. Mayberry RM, Nicewander DA, Qin H, Ballard DJ. Improving quality and reducing inequities: a challenge in achieving best care. World Hosp Health Serv. 2008; 44:16–31.

3. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31:2500–2510.

4. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat. 2013; 137:571–577.

5. Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril. 2012; 97:671–676.

6. Balthazar U, Fritz MA, Mersereau JE. Fertility preservation: a pilot study to assess previsit patient knowledge quantitatively. Fertil Steril. 2011; 95:1913–1916.

7. Balthazar U, Deal AM, Fritz MA, Kondapalli LA, Kim JY, Mersereau JE. The current fertility preservation consultation model: are we adequately informing cancer patients of their options? Hum Reprod. 2012; 27:2413–2419.

8. Matthews ML, Hurst BS, Marshburn PB, Usadi RS, Papadakis MA, Sarantou T. Cancer, fertility preservation, and future pregnancy: a comprehensive review. Obstet Gynecol Int. 2012; 2012:953937.

9. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol. 2010; 28:1284–1286.

10. D'Amour D, Ferrada-Videla M, San Martin Rodriguez L, Beaulieu MD. The conceptual basis for interprofessional collaboration: core concepts and theoretical frameworks. J Interprof Care. 2005; 19:Suppl 1. 116–131.

11. Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril. 2010; 94:1652–1656.

12. Goodman LR, Balthazar U, Kim J, Mersereau JE. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod. 2012; 27:2076–2081.

13. Kohler TS, Kondapalli LA, Shah A, Chan S, Woodruff TK, Brannigan RE. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. J Assist Reprod Genet. 2011; 28:269–277.

14. Vadaparampil S, Quinn G, King L, Wilson C, Nieder M. Barriers to fertility preservation among pediatric oncologists. Patient Educ Couns. 2008; 72:402–410.

15. Adams E, Hill E, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes. Br J Cancer. 2013; 108:1602–1615.

16. Kim J, Deal AM, Balthazar U, Kondapalli LA, Gracia C, Mersereau JE. Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions? Reprod Biomed Online. 2013; 27:96–103.

17. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012; 132:61–73.

18. Manga GP, Shahi PK, Urena MM, Pereira RQ, Plaza MI, Peron YI, et al. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. Breast Cancer. 2010; 17:205–211.

19. Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns. 2002; 48:87–91.

20. Woolf SH, Chan EC, Harris R, Sheridan SL, Braddock CH 3rd, Kaplan RM, et al. Promoting informed choice: transforming health care to dispense knowledge for decision making. Ann Intern Med. 2005; 143:293–300.

21. Street RL Jr, Voigt B, Geyer C Jr, Manning T, Swanson GP. Increasing patient involvement in choosing treatment for early breast cancer. Cancer. 1995; 76:2275–2285.

22. Carlsen B, Aakvik A. Patient involvement in clinical decision making: the effect of GP attitude on patient satisfaction. Health Expect. 2006; 9:148–157.

23. Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006; 15:9–19.

24. Letourneau JM, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012; 118:4579–4588.

25. Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol. 2002; 20:1880–1889.

26. Legare F, O'Connor AC, Graham I, Saucier D, Cote L, Cauchon M, et al. Supporting patients facing difficult health care decisions: use of the Ottawa Decision Support Framework. Can Fam Physician. 2006; 52:476–477.

27. Garvelink MM, ter Kuile MM, Fischer MJ, Louwe LA, Hilders CG, Kroep JR, et al. Development of a Decision Aid about fertility preservation for women with breast cancer in The Netherlands. J Psychosom Obstet Gynaecol. 2013; 34:170–178.

28. Kim J, Oktay K. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control. 2013; 24:421–426.

29. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014; 1:CD001431.

30. Heller L, Parker PA, Youssef A, Miller MJ. Interactive digital education aid in breast reconstruction. Plast Reconstr Surg. 2008; 122:717–724.

31. Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhomme C, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer. 2001; 92:2412–2418.

32. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002; 87:1–7.

33. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol. 2008; 110:345–353.

34. Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni A. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer. 2005; 15:Suppl 3. 206–211.

35. Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol. 2005; 98:263–266.

36. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol. 2007; 25:2928–2937.

37. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997; 90:434–440.

38. Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001; 83:388–393.

39. Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol. 2001; 22:217–220.

40. Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002; 94:2192–2198.

41. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005; 112:317–320.

42. Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol. 2003; 91:569–572.